Protocol Ledger

NCT06355531 · Phase II · ACTIVE NOT RECRUITING

A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)

Interventional Phase II clinical trial protocol NCT06355531 sponsored by Ferrer Internacional in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-07-23 Enrollment: 241 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06355531
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)241 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06355531
Protocol FieldVerified Registry Value
NCT IdentifierNCT06355531
Consolidated Lead SponsorFerrer Internacional
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment241 participants (ACTUAL)
Registered Start Date2024-07-23
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI